DelveInsight’s “ANCA associated Vasculitis Market Insight, Epidemiology And Market Forecast - 2034” report delivers a comprehensive analysis of the ANCA-Associated Vasculitis market, covering historical and forecasted patient pools, current treatment practices, emerging drugs, and market size trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Key Takeaways
-
Market size projection: As per DelveInsight's analysis, the total ANCA-associated Vasculitis market size in the 7MM is expected to surge significantly by 2034, with the market valued at approximately USD 1.5 billion in 2023.
-
Patient population data: The report provides the total ANCA-associated Vasculitis potential pool of approximately 215K diagnosed prevalent cases across the 7MM in 2023, with the United States contributing the highest number of cases, followed by Japan.
-
Key companies: Leading ANCA-associated Vasculitis companies, such as GlaxoSmithKline, AstraZeneca, InflaRx, Staidson BioPharma, Bio-Thera Solutions, and ChemoCentryx/Amgen, are actively developing innovative therapeutic solutions.
-
Pipeline assets: Some of the key ANCA-associated Vasculitis pipeline drugs include Depemokimab (GSK3511294) by GlaxoSmithKline and FASENRA (benralizumab) by AstraZeneca, among others.
-
As per DelveInsight’s patient-based forecasting model, NUCALA (mepolizumab) and rituximab accounted for the highest ANCA-associated Vasculitis market share among available therapies in the 7MM.
-
A comprehensive analysis published in March 2025 noted that ANCA-associated vasculitis drug development has focused on improved b cell targeting through stronger b cell depletion, b cell cytokine inhibition, newer b cell directed cell therapies and broader complement inhibitors inspired by avacopan's success.
-
In April 2025, the FDA approved upadacitinib (Rinvoq) for treating adults with giant cell arteritis (GCA). While this approval is specifically for GCA rather than ANCA-associated vasculitis, it represents significant progress in vasculitis treatment and may have implications for future AAV research.
-
In March 2023, Vifor Fresenius Medical Care Renal Pharma announced that TAVNEOS has been included in the revised EULAR ANCA-associated Vasculitis management recommendations.
-
In September 2023, AstraZeneca reported positive high-level results from the MANDARA Phase III trial for FASENRA, demonstrating non-inferior rates of remission compared to mepolizumab in patients with EGPA.
Discover recent advancements in the ANCA-Associated Vasculitis treatment landscape @ ANCA-Associated Vasculitis Recent Developments.
ANCA-associated Vasculitis Market Dynamics
The ANCA-associated Vasculitis market represents a significant therapeutic opportunity within rare autoimmune diseases, characterized by substantial unmet medical needs and emerging innovative treatment approaches. The current ANCA-associated Vasculitis treatment landscape is dominated by established immunosuppressive therapies, with the market valued at approximately USD 1.5 billion in 2023 across the 7MM countries. This market is experiencing robust momentum driven by the launch of novel targeted therapies and an improved understanding of disease pathophysiology.
ANCA-associated Vasculitis market drivers include the recent approval and commercial success of TAVNEOS (avacopan), the first-in-class complement 5a receptor (C5aR) antagonist that represents a paradigm shift in ANCA-associated Vasculitis treatment. The current treatment paradigm relies heavily on cyclophosphamide, rituximab, and high-dose corticosteroids for remission induction, followed by maintenance therapy with methotrexate or azathioprine. While these therapies demonstrate efficacy in inducing and maintaining remission, they are associated with significant toxicities, creating substantial opportunities for safer, more targeted interventions.
The ANCA-associated Vasculitis emerging therapies focus on precision targeting of inflammatory pathways involved in vasculitic processes. TAVNEOS operates through a novel mechanism by blocking the complement 5a receptor, effectively interrupting the complement-driven inflammatory cascade that characterizes ANCA-associated Vasculitis. Similarly, the IL-5 pathway targeting approach employed by therapies like FASENRA (benralizumab) and Depemokimab represents a sophisticated understanding of eosinophil-mediated pathology, particularly relevant in EGPA management.
ANCA-associated Vasculitis clinical development activity remains robust, with multiple Phase III trials demonstrating the industry's commitment to addressing this rare disease population. The MANDARA trial for FASENRA represents the first head-to-head comparison of biologics in EGPA, while the ongoing OCEAN trial for Depemokimab promises to further expand treatment options. The competitive landscape includes major pharmaceutical companies such as GlaxoSmithKline, AstraZeneca, and InflaRx, each pursuing distinct therapeutic approaches and patient populations.
Despite significant progress, the market faces challenges, including diagnostic delays that lead to increased morbidity and mortality, highlighting the critical need for reliable biomarkers and early detection strategies. However, these challenges simultaneously represent opportunities for companies developing diagnostic tools and precision medicine approaches. Future market growth is expected to be driven by the anticipated launch of emerging therapies, improved diagnostic capabilities, and expanding understanding of disease heterogeneity across the three main subtypes: granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis.
Download the ANCA-Associated Vasculitis Market report to understand which factors are driving the therapeutic market @ ANCA-Associated Vasculitis Market Trends.
ANCA-associated Vasculitis Epidemiology
The epidemiological landscape of ANCA-associated Vasculitis across the 7MM reveals a complex distribution pattern with significant regional variations and distinct subtype prevalence characteristics. The total diagnosed prevalent cases reached approximately 215K across the seven major markets in 2023, establishing a substantial patient population requiring specialized therapeutic interventions. This patient population represents individuals affected by three primary disease subtypes: granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis, each presenting unique clinical challenges and treatment requirements.
Epidemiological segmentation demonstrates interesting patterns in disease distribution and organ involvement. Among the three ANCA-associated Vasculitis subtypes, granulomatosis with polyangiitis shows higher prevalence compared to microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis across most markets. However, regional variations exist, with Japan showing a different pattern where microscopic polyangiitis accounts for the highest number of cases, followed by granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis. This geographic variation reflects genetic, environmental, and potentially diagnostic practice differences across regions.
The total eligible patient pool encompasses individuals across various stages of disease severity and organ involvement patterns. In the United States, diagnosed prevalent cases of microscopic polyangiitis by organ involvement show renal impairment as the most common manifestation, followed by lower respiratory tract involvement, cutaneous manifestation, gastrointestinal involvement, nervous system involvement, upper respiratory tract involvement, cardiovascular involvement, and eye involvement. For granulomatosis with polyangiitis cases in the UK, organ involvement patterns include upper respiratory tract, eye involvement, lower respiratory tract, cutaneous manifestation, renal impairment, and nervous system involvement.
Geographic segmentation across the 7MM reveals the United States as the largest market by patient population, accounting for the highest number of diagnosed prevalent cases in 2023, followed by Japan as the second-largest market. The EU4 countries (Germany, France, Italy, Spain) and the UK collectively represent a significant portion of the global patient population, with granulomatosis with polyangiitis accounting for the highest number of cases in these regions. The forecast period from 2024 to 2034 anticipates continued growth in diagnosed cases, driven by improved diagnostic capabilities, increased disease awareness, and enhanced healthcare access across all geographic regions within the 7MM framework.
Discover evolving trends in the ANCA-Associated Vasculitis patient pool forecasts @ ANCA-Associated Vasculitis Epidemiology Analysis.
Key ANCA-associated Vasculitis Companies and Treatment Market
The clinical and regulatory landscape for ANCA-associated Vasculitis treatment is characterized by a dynamic ecosystem of established therapies and emerging innovations that collectively address the complex pathophysiology of these rare autoimmune conditions. Current treatment options follow a well-established two-phase approach consisting of remission-induction therapy utilizing cyclophosphamide, rituximab, and high-dose steroids, followed by remission-maintenance treatment with methotrexate or azathioprine. The introduction of TAVNEOS (avacopan) as an FDA-approved adjunctive treatment represents a significant advancement in the therapeutic arsenal, offering patients a complement-targeted approach that addresses the underlying inflammatory cascade driving disease pathology.
ANCA-associated Vasculitis clinical pipeline activity demonstrates robust pharmaceutical industry engagement with multiple companies pursuing diverse therapeutic strategies across various development phases. Key players include GlaxoSmithKline (Depemokimab/GSK3511294), AstraZeneca (FASENRA/benralizumab), InflaRx, Staidson BioPharma, Bio-Thera Solutions, and ChemoCentryx/Amgen (TAVNEOS/avacopan). These companies represent a comprehensive approach to addressing different aspects of ANCA-associated Vasculitis pathophysiology, from complement inhibition to IL-5 pathway targeting, reflecting the scientific community's sophisticated understanding of disease mechanisms.
Market positioning of current and emerging therapies reflects their distinct mechanisms of action and clinical applications within the treatment paradigm. TAVNEOS occupies a unique position as the first-in-class oral complement 5a receptor antagonist, offering patients an alternative to traditional immunosuppressive approaches while maintaining compatibility with standard therapy regimens. NUCALA (mepolizumab) and rituximab currently account for the highest market share among available therapies, establishing their central role in current treatment protocols.
Drug profiles reveal diverse approaches to targeting ANCA-associated Vasculitis pathophysiology. Depemokimab represents a next-generation humanized anti-IL-5 monoclonal antibody with extended half-life and improved affinity compared to approved therapies, currently advancing through Phase III development in the OCEAN trial. FASENRA employs a direct IL-5 receptor alpha binding mechanism that attracts natural killer cells to induce rapid eosinophil depletion, with the MANDARA trial demonstrating non-inferior remission rates compared to mepolizumab in a head-to-head comparison. Development milestones include positive Phase III results for FASENRA in September 2023 and the ongoing OCEAN trial for Depemokimab with anticipated data release after 2025. Commercial arrangements encompass various licensing deals and strategic collaborations, with Vifor Fresenius Medical Care Renal Pharma securing European marketing authorization for TAVNEOS and its inclusion in revised EULAR management recommendations, representing significant regulatory and clinical guideline achievements.
Discover which companies are innovating in the ANCA-Associated Vasculitis treatment landscape @ ANCA-Associated Vasculitis Competitive Landscape.
Conclusion
The ANCA-associated Vasculitis market stands at a pivotal juncture, with substantial growth potential driven by innovative therapeutic approaches and an expanding understanding of disease pathophysiology. DelveInsight's comprehensive market analysis reveals a robust pipeline of targeted therapies poised to transform treatment outcomes for patients across the 7MM, while addressing the significant unmet medical needs that characterize this complex rare disease landscape. The convergence of novel mechanisms of action, improved diagnostic capabilities, and strategic pharmaceutical industry investment positions this market for sustained growth and enhanced patient outcomes throughout the forecast period, extending to 2034.
Table of Contents
1. Key Insights
2. Executive Summary of ANCA-Associated Vasculitis
3. Competitive Intelligence Analysis for ANCA-Associated Vasculitis
4. ANCA-Associated Vasculitis Market Overview at a Glance
5. ANCA-Associated Vasculitis: Disease Background and Overview
6. ANCA-Associated Vasculitis Patient Journey
7. ANCA-Associated Vasculitis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. ANCA-Associated Vasculitis Unmet Needs
10. Key Endpoints of ANCA-Associated Vasculitis Treatment
11. ANCA-Associated Vasculitis Marketed Products
12. ANCA-Associated Vasculitis Emerging Therapies
13. ANCA-Associated Vasculitis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of ANCA-Associated Vasculitis
17. KOL Views
18. ANCA-Associated Vasculitis Market Drivers
19. ANCA-Associated Vasculitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
